| Patient | Frédéric Chopin |
|---|---|
| Date of birth | 1810-03-01 |
| Identifiers | MRN HR-NI020-SYN-TD; SSN (made up) 000-20-8845 |
| Document date | 1838-04-07 |
| Author | Matthias Lindqvist, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-and-a-half-week review: release from isolation, return to teaching, liver tests, and tests for the alternatives. [S]
Mr. Chopin returns after nineteen days of treatment, all observed by video. The night sweats stopped in the second week, he has had no fever for ten days and no blood in his sputum for twelve, and his cough is now occasional. He had mild nausea in the first week, eased by taking the tablets in the middle of breakfast, and his urine and tears are orange as expected. He has no tendon pain, tingling, yellowing, dark urine, or rash. The three sputum smears collected in the third week were all negative, and the health department released him from isolation two days ago; he will start teaching in his studio again this week, beginning with eight lessons. The baseline cultures are growing Mycobacterium tuberculosis complex, and the molecular tests show no mutations for isoniazid or fluoroquinolone resistance. He has seen the dietitian twice and drinks two supplements a day in the afternoon and evening. His mood is better now that he can see his students. The sweat chloride test was done this morning. [S]
| Element | Detail |
|---|---|
| Treatment | Nineteen of nineteen doses observed |
| Infection control | Three negative smears; released from isolation; teaching again this week |
| Microbiology | Cultures growing M. tuberculosis complex; no isoniazid or fluoroquinolone resistance mutations |
| Weight | 49.6 kg, up 1.1 kg |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Occasional cough; no blood for twelve days |
| Constitutional | Negative | No fever or night sweats; appetite returning |
| Gastrointestinal | Negative | Nausea gone; no abdominal pain or jaundice |
| Musculoskeletal | Negative | No tendon or joint pain |
| Neurological | Negative | No numbness or tingling |
| Psychiatric | Negative | Mood better; no thoughts of suicide or self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Rifapentine 150 mg tablets, eight tablets (1200 mg) daily with food | 1200 mg once daily with a meal by video-observed therapy with the health department, seven days a week, for 17 weeks (119 doses) | Oral route | 1838-03-20 to 1838-07-16 | completed | S |
| Moxifloxacin 400 mg tablet, one tablet daily | 400 mg once daily with the other drugs by video-observed therapy with the health department, seven days a week, for 17 weeks; no mineral supplements within 4 hours before or 8 hours after | Oral route | 1838-03-20 to 1838-07-16 | completed | S |
| Isoniazid 300 mg tablet, one tablet daily | 300 mg once daily by video-observed therapy with the health department, seven days a week, for 17 weeks | Oral route | 1838-03-20 to 1838-07-16 | completed | S |
| Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily | 1000 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase (weight band 40 to under 55 kg) | Oral route | 1838-03-20 to 1838-05-14 | completed | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 1838-03-20 to 1838-07-16 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1838-04-07 | Body height | 170 | cm | S |
| 1838-04-07 | Body weight | 49.6 | kg | S |
| 1838-04-07 | Body mass index (BMI) [Ratio] | 17.2 | kg/m2 | S |
| 1838-04-07 | Systolic blood pressure | 106 | mm[Hg] | S |
| 1838-04-07 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 1838-04-07 | Heart rate | 86 | /min | S |
| 1838-04-07 | Respiratory rate | 16 | /min | S |
| 1838-04-07 | Body temperature | 37 | Cel | S |
| 1838-04-07 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1838-04-07 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 34 | U/L | 7-56 U/L | Normal | S |
| 1838-04-07 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 10-40 U/L | Normal | S |
| 1838-04-07 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1838-04-07 | Chloride [Moles/volume] in Sweat | 18 | mmol/L | <=29 mmol/L | Normal | S |
| 1838-04-07 | Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma by Nephelometry | 142 | mg/dL | 100-190 mg/dL | Normal | S |
Vital signs recorded on 1838-04-07; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Thin, brighter; weight 49.6 kg; temperature 37.0 °C |
| Eyes | No icterus |
| Respiratory | A few crackles at the right apex; no bronchial breathing |
| Musculoskeletal | Tendons non-tender |
| Neurological | Normal sensation in the fingers and feet |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Cough for about three months, blood-streaked sputum for two weeks, night sweats, and weight loss of about 6 kg in a man of 28, with a right upper lobe cavity on chest X-ray and CT: suspected pulmonary tuberculosis; home airborne isolation and three sputum samples for acid-fast smear, nucleic acid amplification, and culture | resolved | confirmed | R04.2 | S — Synthetic presenting problem linked to his documented chronic cough and hemoptysis; superseded by the diagnosis at the second visit. |
| Pulmonary tuberculosis of the right upper lobe, cavitary and sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistance | active | confirmed | A15.0 | S — Synthetic modern coding of his documented tuberculosis, chosen over the disputed genetic and cardiac alternatives; the cavity and all bacteriology are synthetic. |
| Moderate protein-calorie malnutrition: BMI 16.8, about 11 percent weight loss in three months, and albumin 3.2 g/dL | active | confirmed | E44.0 | S — Synthetic nutrition diagnosis anchored to his documented frailty and exhaustion. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, hemoptysis, fever, night sweats | Every visit | Completed today | Occasional cough; no fever, sweats, or blood |
| Examination | Weight, with the pyrazinamide dose checked against the weight band | Monthly | Completed today | 49.6 kg; pyrazinamide band unchanged |
| Medication safety | Adverse effects: hepatitis symptoms, tendon pain, numbness or tingling, rash, nausea, orange body fluids | Every visit | Completed today | Early nausea resolved; no tendon pain, tingling, rash, or jaundice |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline; repeat for symptoms or risk factors (here at two to three weeks, for low weight and albumin) | Completed today | ALT 34, AST 31 U/L, bilirubin 0.8 mg/dL, all normal |
| Laboratory | Sputum acid-fast smear and culture | Baseline, then monthly until two consecutive cultures are negative | Completed today | Three smears in the third week negative; baseline cultures growing M. tuberculosis complex; third-week cultures pending |
| Laboratory | Rapid molecular testing for isoniazid and fluoroquinolone resistance | At baseline | Completed today | No isoniazid (katG, inhA) or fluoroquinolone (gyrA, gyrB) resistance mutations |
| Laboratory | Phenotypic susceptibility (rifampin, isoniazid, pyrazinamide, moxifloxacin) | At baseline | Ordered | Set up on the baseline isolate; pending |
| Medication safety | Doses observed and the completion clock (56 doses within 70 days, 63 within 84 days, 119 within five months) | Every visit | Completed today | Nineteen of nineteen doses observed |
| Self-management | Home airborne isolation and the release criteria | Until three negative smears, clinical improvement, and two weeks of treatment | Completed today | Release criteria met; released by the health department two days ago |
| Referral | Contact investigation (students, friends, close contacts) | Led by the health department from diagnosis | Referred | In progress with the health department; no results in his record |
| Self-management | Nutrition: dietitian, intake, supplement drinks | Every visit until weight is restored | Completed today | Two dietitian visits; two supplement drinks a day, apart from the dose |
| Laboratory | Sweat chloride and serum alpha-1 antitrypsin | Once, to address the alternatives | Completed today | Sweat chloride 18 mmol/L; alpha-1 antitrypsin 142 mg/dL; both normal |
| Survey | Depression screen (PHQ-9) | At diagnosis, at two months, and at the end of treatment | Not indicated | Next at two months; mood better today |
Goal progress:
Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation (2017); American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency (2003); Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012)
Follow-up: End-of-intensive-phase review in about five weeks, with the two-month sputum culture, liver tests, a blood count, and the PHQ-9. Next scheduled visit 1838-05-15: end of the eight-week intensive phase: susceptibility results, the two-month sputum culture, and the start of the continuation phase. [S]